Neurocrine Biosciences Inc $ 95.78 -1.07 (-1.1%)
Volume:
1,037,150
Avg Vol (1m):
694,506
Market Cap $:
8.77 Bil
Enterprise Value $:
8.62 Bil
P/E (TTM):
736.76
P/B:
17.95
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
| Graham Number | ||
|
Price: $95.78 | ||
Manual of Stocks™ Web
Financial Strength | 5.8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.33 | ||
| Equity-to-Asset | 0.45 | ||
| Debt-to-Equity | 0.96 | ||
| Debt-to-EBITDA | 8.3 | ||
| Interest Coverage | 0.31 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 8.36 | ||
| Beneish M-Score | -1.86 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 1.6 | ||
| Net Margin % | 2.98 | ||
| ROE % | 4.11 | ||
| ROA % | 1.88 | ||
| ROC (Joel Greenblatt) % | 76.77 | ||
| 3-Year Revenue Growth Rate | 172.4 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 736.76 | ||
| Forward PE Ratio | 24.57 | ||
| PE Ratio without NRI | 736.76 | ||
| Price-to-Owner-Earnings | 1349.01 | ||
| PB Ratio | 17.95 | ||
| PS Ratio | 14.96 | ||
| Price-to-Free-Cash-Flow | 240.05 | ||
| Price-to-Operating-Cash-Flow | 140.61 | ||
| EV-to-EBIT | 171.29 | ||
| EV-to-EBITDA | 153.85 | ||
| EV-to-Revenue | 14.26 | ||
| Current Ratio | 7.44 | ||
| Quick Ratio | 7.32 | ||
| Days Inventory | 525.95 | ||
| Days Sales Outstanding | 57.51 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 17.97 | ||
| Price-to-Median-PS-Value | 0.42 | ||
| Price-to-Graham-Number | 24.25 | ||
| Earnings Yield (Greenblatt) % | 0.58 |